UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating

Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a ‘Buy’ rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 sales guidance.

UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating

The biopharmaceutical company is facing weakness in its diagnostic segment. However, the weakness has not altered UBS’s positive stance on the company. That’s because the company is experiencing robust growth, with its MedTech division recording 12.2% organic growth in the second quarter, higher than the consensus estimate of 11.2%.

In addition, UBS is buoyed by Abbott’s 6.9% organic sales growth or 7.5% on excluding COVID diagnostics. The research firm expects robust growth in other segments, including the MedTech pipeline, to offset weakness in the diagnostic segment.

Abbott Laboratories (NYSE:ABT) is a global healthcare company focused on creating life-changing technologies and products that span diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It is focused on improving health and well-being across all stages of life through innovative solutions and a commitment to accessibility.

While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best 52-Week High Stocks to Buy Now and 10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen.

Disclosure: None. This article is originally published at Insider Monkey.